Why MediciNova, Inc.’s (MNOV) Stock Is Up 9.20%
As of Friday, October 02, MediciNova, Inc.’s MNOV share price has surged by 9.20%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Commentary & Analysis
Why MediciNova, Inc.’s (MNOV) Stock Is Up 10.74%
As of Friday, October 02, MediciNova, Inc.’s MNOV share price has surged by 10.74%, which has investors questioning if this is right time to sell.Omar Beirat
Why MediciNova, Inc.’s (MNOV) Stock Is Down 9.90%
As of Wednesday, September 30, MediciNova, Inc.’s MNOV share price has dipped by 9.90%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MediciNova, Inc.’s (MNOV) Stock Is Down 7.66%
As of Tuesday, September 29, MediciNova, Inc.’s MNOV share price has dipped by 7.66%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why MediciNova, Inc.’s (MNOV) Stock Is Down 14.52%
As of Tuesday, September 29, MediciNova, Inc.’s MNOV share price has dipped by 14.52%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $71.4 | $216.5 | 19% |
|
| Shares Out (Mil) | 49.2 | 53.9 | 47% |
|
| Institutional Ownership | 78.6% | 93.0% | 48% |
|
| Float (Mil) | 42.9 | 40.9 | 43% |
|
| Beta | 0.62 | 0.95 | 36% |
|
| Avg Daily Volume (000s) | 119 | 616 | 38% |
|
| Price Change (52-week) |
16.5% | 46.9% | 66% |
|
| Growth | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 2.9% | (10.2%) | 44% |
|
| EPS (5yr) | 4.7% | 15.7% | 38 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.9%) | (15.7%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($0.060) | ($0.257) | ($0.515) | |
| Month Ago EPS | ($0.060) | ($0.280) | ($0.450) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.060) | ($0.260) | ($0.430) | |
| Year/Year Chg | 27.7% | 4.9% | (214.3%) | |
| Financials | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($11) | ($44) | 29% |
|
| EPS (TTM) | ($0.219) | ($1.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($33) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $43 | $174 | 15% |
|
| Valuation | MNOV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.91 | 2.21 | 51% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.7% | 66.0% | 46% |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (23.8%) | (47.2%) | 19% |
|
| ROE | (25.6%) | (54.2%) | 21% |
|
| Liabilities to Assets | 7.8% | 29.1% | 4% |
|
| F-Score | 2 | 2 | 7% |
|
MediciNova, Inc. did not pass any screens on 10/15/2026.
